Curiox Biosystems - Public Comps and Valuation Multiples

Curiox Biosystems Overview

About Curiox Biosystems

Curiox Biosystems Co Ltd is Korean Based company which brings together decades of scientific and engineering expertise in surface chemistry and life science instrumentation with the goal of overcoming critical challenges that slow the pace of life science research. The company has introduced Laminar Wash technology, which automates cell processing and enables highly reproducible and high-throughput cell analysis. The company offers various products such as LAMINAR WASH AUTO 1000 SYSTEM, Curiox Laminar Wash HT2000 System and Laminar Wash MINI System.

Founded

2018

HQ

Employees

n/a

Website

curiox.co.kr

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $3.3M

LTM EBITDA -$7.7M

EV

$735M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Curiox Biosystems Financials

As of August 2025, Curiox Biosystems reported last 12-month revenue of $3.3M and EBITDA of -$7.7M.

In the same period, Curiox Biosystems generated $1.8M in LTM gross profit and -$5.7M in net income.

See Curiox Biosystems valuation multiples based on analyst estimates

Curiox Biosystems P&L

In the most recent fiscal year, Curiox Biosystems reported revenue of $3.3M and EBITDA of -$3.3M.

Curiox Biosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Curiox Biosystems valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$3.3M	XXX	$3.3M	XXX	XXX	XXX
Gross Profit	$1.8M	XXX	$1.8M	XXX	XXX	XXX
Gross Margin	57%	XXX	56%	XXX	XXX	XXX
EBITDA	-$7.7M	XXX	-$3.3M	XXX	XXX	XXX
EBITDA Margin	-235%	XXX	-103%	XXX	XXX	XXX
EBIT	-$9.5M	XXX	-$9.5M	XXX	XXX	XXX
EBIT Margin	-291%	XXX	-292%	XXX	XXX	XXX
Net Profit	-$5.7M	XXX	-$5.7M	XXX	XXX	XXX
Net Margin	-176%	XXX	-176%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Curiox Biosystems including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $3.3M. EBITDA for the last twelve months was -$7.7M. In the most recent fiscal year, Curiox Biosystems achieved $3.3M in revenue and -$3.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$3.3M	Analyst estimates available to subscribers	$3.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.8M	Analyst estimates available to subscribers	$1.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	56.5% gross margin	Analyst estimates available to subscribers	55.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$7.7M	Analyst estimates available to subscribers	-$3.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-234.8% EBITDA margin	Analyst estimates available to subscribers	-102.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$9.5M	Analyst estimates available to subscribers	-$9.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-291.3% EBIT margin	Analyst estimates available to subscribers	-291.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$5.7M	Analyst estimates available to subscribers	-$5.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-176.1% net profit margin	Analyst estimates available to subscribers	-176.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Curiox Biosystems

This financial data table provides comprehensive performance metrics for Curiox Biosystems, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Curiox Biosystems generated $3.3M in revenue over the last twelve months.
The company achieved -$7.7M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.8M.
Net income over the last twelve months reached -$5.7M.

Fiscal Year Performance

In the most recent fiscal year, Curiox Biosystems reported $3.3M in total revenue.
Fiscal year EBITDA was -$3.3M.
The company maintained a gross profit margin of 55.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was -102.8%.
Net profit margin reached -176.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Curiox Biosystems. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Curiox Biosystems Stock Performance

Curiox Biosystems has current market cap of KRW 1.05T (or $745M), and EV of KRW 1.04T (or $735M).

Market Cap Evolution

Curiox Biosystems Stock Data

As of September 30, 2025, Curiox Biosystems's stock price is KRW 65000 (or $46).

See Curiox Biosystems trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$735M	$745M	XXX	XXX	XXX	XXX	$-0.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Curiox Biosystems Valuation Multiples

Curiox Biosystems's trades at 226.1x EV/Revenue multiple, and -219.9x EV/EBITDA.

See valuation multiples for Curiox Biosystems and 15K+ public comps

Curiox Biosystems Financial Valuation Multiples

As of September 30, 2025, Curiox Biosystems has market cap of $745M and EV of $735M.

Equity research analysts estimate Curiox Biosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Curiox Biosystems has a P/E ratio of -129.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$745M	XXX	$745M	XXX	XXX	XXX
EV (current)	$735M	XXX	$735M	XXX	XXX	XXX
EV/Revenue	225.4x	XXX	226.1x	XXX	XXX	XXX
EV/EBITDA	-96.0x	XXX	-219.9x	XXX	XXX	XXX
EV/EBIT	-77.4x	XXX	-77.5x	XXX	XXX	XXX
EV/Gross Profit	398.9x	XXX	n/a	XXX	XXX	XXX
P/E	-129.7x	XXX	-129.9x	XXX	XXX	XXX
EV/FCF	-95.1x	XXX	-104.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Curiox Biosystems Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Curiox Biosystems Margins & Growth Rates

Curiox Biosystems's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Curiox Biosystems's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Curiox Biosystems's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Curiox Biosystems and other 15K+ public comps

Curiox Biosystems Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-235%	XXX	-103%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	34%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	55%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	347%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial